PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Samsara Inc. (IOT)
33.600.80 (-2.33%)
33.44 - 34.57
31.40 - 61.90
7.61M / 5.87M (Avg.)
-152.73 | -0.22
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.55%
Revenue growth above 1.5x MDB's 3.59%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
8.14%
Gross profit growth above 1.5x MDB's 1.35%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
60.83%
EBIT growth below 50% of MDB's 219.83%. Michael Burry would suspect deeper competitive or cost structure issues.
61.13%
Operating income growth above 1.5x MDB's 33.41%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
70.37%
Net income growth under 50% of MDB's 261.89%. Michael Burry would suspect the firm is falling well behind a key competitor.
-110.47%
Negative EPS growth while MDB is at 253.85%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-110.47%
Negative diluted EPS growth while MDB is at 246.15%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.84%
Share count expansion well above MDB's 0.72%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.84%
Diluted share count expanding well above MDB's 0.72%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
49.55%
OCF growth 1.25-1.5x MDB's 34.99%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
55.30%
Positive FCF growth while MDB is negative. John Neff would see a strong competitive edge in net cash generation.
88.33%
10Y revenue/share CAGR under 50% of MDB's 890.19%. Michael Burry would suspect a lasting competitive disadvantage.
88.33%
5Y revenue/share CAGR under 50% of MDB's 239.09%. Michael Burry would suspect a significant competitive gap or product weakness.
35.59%
3Y revenue/share CAGR under 50% of MDB's 84.86%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
166.35%
10Y OCF/share CAGR under 50% of MDB's 370.82%. Michael Burry would worry about a persistent underperformance in cash creation.
166.35%
Below 50% of MDB's 547.90%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
154.90%
3Y OCF/share CAGR 1.25-1.5x MDB's 103.48%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
87.21%
Net income/share CAGR at 50-75% of MDB's 139.20%. Martin Whitman might question if the firm’s product or cost base lags behind.
87.21%
5Y net income/share CAGR at 50-75% of MDB's 119.32%. Martin Whitman might see a shortfall in operational efficiency or brand power.
97.82%
3Y net income/share CAGR 75-90% of MDB's 116.83%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
182.87%
Below 50% of MDB's 624.85%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
182.87%
Below 50% of MDB's 2464.64%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-46.77%
Negative 3Y equity/share growth while MDB is at 274.87%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.94%
AR growth well above MDB's 17.47%. Michael Burry fears inflated revenue or higher default risk in the near future.
-1.16%
Inventory is declining while MDB stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
8.61%
Asset growth 1.25-1.5x MDB's 6.37%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
6.12%
Under 50% of MDB's 83.91%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-6.60%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-4.82%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-1.35%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.